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Abstract 
 
The Medium Spiny Neuron (MSN) composes approximately 95% of the neurons in the striatum 
in the brain. MSNs are GABAergic neurons that modulate the movement and reward pathways. 
Cortical and substantia nigra pars compacta neurons release glutamate and dopamine on MSNs, 
respectively. These inputs are required for the MSN to grow into its typical highly branched, 
spiny morphology. The Lanier lab found that dopamine increases dendritic branching in the 
developing MSN. The goal of the current study is to find the mechanism by which dopamine 
enhances MSN dendritic arborization. The hypothesis is that dopamine increases dendritic 
branching by binding a D1-D2 heteromer coupled to Gq, which a activates phospholipase C 
(PLC) dependent mechanism. A striatal-cortical co-culture prepared from day 16 mouse embryos 
was used to grow MSNs with their afferent cortical neurons. The experimental treatments were: 
1) D1 receptor agonist SKF81297, D2 receptor agonist quinpirole, and both SKF81297 & 
quinpirole, 2) chemogenetic activation of Gq, and 3) PLC antagonist U73122. Treatments were 
administered in vitro at day 4, and regularly administered until fixation at day 19. It was found 
that SKF81297 and quinpirole, together and in isolation, were not able to replicate dopamine’s 
increased branching effect. In addition, it was found that Gq activation, using a chemogenetic 
approach, mimicked dopamine’s effect. Further, U73122 had no effect on branching on its own, 
but U73122 significantly attenuated dopamine’s branching effects. Taken together, this data 
support the hypothesis that dopamine enhances branching by binding a D1-D2 heteromer 
coupled to Gq, to activate a PLC-dependent mechanism.  
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1 Introduction 
 
1.1 Background 
 
  A neuron is a cell that forms treelike branches called dendrites, which allow it to receive 
information in the form of neurotransmitters. In a mature neuron, axon release of 
neurotransmitter into a synapse results in a well characterized response, where a neurotransmitter 
diffuses across the synapse and binds receptor on the receiving (post synaptic) neuron’s dendrite. 
However, in the developing brain, neurons express plasma membrane receptors for 
neurotransmitters before they even form synapses (Burden and Scheiffele, 2013). Nearby neural 
tissue synthesizes and releases neurotransmitters, which diffuse through the interstitium, bind 
local cells, and influence their development (Herlenius and Lagercrantz, 2004). Without 
exposure to neurotransmitters during this critical period in development, a neuron will not grow 
into its expected morphology, which can result in neurodevelopmental disorders such as autism 
(Money and Stanwood, 2013). Our previous work found that the neurotransmitter dopamine 
increases the dendritic branching of a developing Medium Spiny Neuron (MSN) (Penrod et al., 
2015). The objective of the current study is to find the mechanism dopamine initiates to increase 
branching. Our hypothesis is that dopamine binds a D1-D2 heteromer coupled to Gq to activate a 
phospholipase C (PLC) dependent mechanism.   
MSNs are medium-sized and possess highly branched dendrites with a spherical dendritic 
arbor, meaning the dendrites radiate out from the soma equally in every direction. These 
dendrites are covered in tiny spines, hence the name Medium Spiny Neuron. Forming an 
extensive dendritic arbor and growing dendritic spines are crucial events that must occur during 
MSN development for normal brain function (Klapstein et al., 2001; Nishijima et al. 2014). 
MSNs compose approximately 95% of the neurons of the striatum, a brain structure that plays an 
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important role in movement, cognitive functions, and emotional-motivational behavior (Yager et 
al., 2015; Langen et al., 2011). The striatum is divided into the ventral striatum and the dorsal 
striatum. The ventral striatum contains the nucleus accumbens and the dorsal striatum contains 
the caudate and putamen. Both parts of the striatum receive input from almost all areas of cortex 
and the substantia nigra pars compacta. Cortical neurons release glutamate on MSNs, while the 
substantia nigra pars compacta neurons release dopamine. In turn, MSNs release GABA, an 
inhibitory neurotransmitter, onto other regions of the basal ganglia, a group of brain structures 
involved with movement and the reward pathways (Lanciego et al., 2012). For example, when a 
neuron in the motor cortex is activated, it will release the excitatory neurotransmitter glutamate 
onto an MSN, which will inhibit downstream basal ganglia neurons, enabling a person’s 
voluntary movements to be smooth.    
The level of dendritic branching in neurons is highly developmentally regulated. Early in 
brain development, neurons rapidly form an extensive, highly branched dendritic arbor, and thus 
establish many synaptic contacts. Postnatally, dendrites are slowly pruned over time, which is 
crucial for enabling the neuron to integrate and properly respond to all of the exogenous input it 
receives. In the human cortex, the dendritic pruning process begins at 3 months postnatal and 
continues until approximately 16 years old, during which time 40% of cortical synapses are lost 
(Karlsgodt et al., 2008). However, an overactive pruning process that too drastically reduces 
dendritic branching is thought to result in schizophrenia (McGlashan, 2000). To avoid disease 
phenotypes, neurons must have appropriate levels of dendritic branching so the right amount of 
synapses are present at every developmental stage (Kalsgodt et al., 2008).   
Fully developed neurons must also maintain sufficient dendritic branching for normal 
function. Mature MSNs with stunted dendrites and a reduced spine density are implicated in 
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neurodegenerative diseases such as dementia with Lewy bodies, Huntington’s disease, and 
Parkinson’s disease (Zaja-Milatovic et al., 2006; Klapstein et al., 2001; Deutch, Colbran, and 
Winder, 2006). Huntington’s disease (HD), also called “the disease of the striatum”, provides the 
most direct example (Ehrlich 2012). HD is a genetic disorder characterized by the expansion of a 
CAG repeat coding for the huntingtin protein. Too many repeats encodes for mutated huntingtin 
protein that accumulates in neurons, forming aggregates that interfere with normal cell function 
and eventually cause neuronal death. MSNs are the first cell type to die in HD (Han et al., 2010). 
However, carriers of the HD mutation show behavioral symptoms far before striatal neurons 
atrophy or any other clear neurological symptoms can be detected (Lerner et al., 2012). The 
remaining MSNs in post-mortem HD brains show a reduced dendritic arbor and low spine 
density. It is believed that HD neurodegeneration begins with these morphological changes 
(Baquet, Gorski, and Jones 2004), which are associated with loss of MSN function and a 
decreased ability to generate action potentials (Lerner et al., 2012; Klapstein et al., 2001). Early 
behavioral HD symptoms such as apathy and depression are attributed to MSN dysfunction, 
while MSN death contributes to jerky, uncontrolled tremors (Miller et al., 2008; Han et al., 
2010). Another example of the importance of MSN morphology occurs when afferent 
projections into the striatum are lost. In Parkinson’s disease (PD), dopaminergic substantia nigra 
neurons atrophy, which results in reduced dopamine release on MSNs. MSNs respond to the 
absence of signal by decreasing their dendritic length and spine density (Deutch, Colbran, and 
Winder, 2006). This leads to impaired MSN function, contributing to the lack of motor control 
seen in PD patients (Deutch, Colbran, and Winder, 2006).  
Many neurological, psychiatric, and mood disorders can be treated by targeting dopamine 
signaling pathways (Beaulieu and Gainetdinov, 2011; Cannon et al., 2008). The results of the 
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current study could hold clinical relevance for pregnant women taking dopamine receptor 
agonists/antagonists capable of crossing the placental barrier. The drug could alter fetal MSN 
branching or spine density. Deviations from typical MSN morphology and inability of MSNs to 
transmit information are highly correlated events (Klapstein et al., 2001). Thus, MSNs cannot 
integrate all of the cortical input they receive, resulting in an impaired striatal-cortical pathway. 
Impaired striatal-cortical circuits are implicated in repetitive human behaviors, including 
obsessive compulsive disorder (OCD) and Tourette’s syndrome (Shmelkov et al., 2010).  
Glutamate and dopamine are two neurotransmitters that are particularly influential in 
shaping MSN morphology. Contact with glutamatergic neurons is needed to induce spine 
formation in MSNs (Segal, Greenberger, and Korkotian 2003). Spines are the postsynaptic sites 
on MSNs where neurotransmitter binds receptor. Without spines, a Medium Spiny Neuron 
cannot perform its function of receiving and responding to glutamatergic and dopaminergic 
input. Until 2011, in vitro MSN research was conducted primarily on spineless MSNs, due to the 
lack of glutamatergic afferents in the culture. To produce MSNs with spines in vitro, our lab 
pioneered the striatal cortical co-culture method, which allows cortical neurons to synapse 
directly on striatal neurons (Penrod et al., 2011). The importance of forming synapses in the 
striatal-cortical co-culture cannot be understated. No-contact treatments were performed in 
which striatal tissue was grown in the same dish—but physically separated from—cortical tissue, 
which enabled MSNs to uptake secretions that cortical neurons released into the media (Penrod 
et al., 2015). Cortical neurons secrete glutamate, brain-derived neurotrophic factor (BDNF), and 
many other molecules that directly enhance MSN growth (Rauskolb et al., 2010). Our lab found 
that the striatal cortical co-culture had dramatically increased dendritic arborization and spine 
density in MSNs, in comparison to the MSNs grown in no-contact cultures (Penrod et al., 2015). 
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Further, the striatal-cortical co-culture is reliable and produces robust, healthy MSNs that 
resemble their in vivo counterparts on morphological and electrical measures (Penrod et al., 
2011). In these striatal-cortical co-cultures, no substantia nigra tissue is present; thus, no 
dopaminergic neurons are present. Because of this, dopamine addition can be precisely 
controlled. Chronic dopamine administration to the co-cultures caused a significant increase in 
MSN dendritic branching compared to MSNs grown in co-cultures without dopamine (Penrod et 
al., 2015).  
Dopamine can bind and activate all dopamine receptors. The canonical mechanism 
involves dopamine activating a single, monomeric G protein coupled receptor (GPCR), either D1 
or D2, as shown in Figure 1. The D3, D4, and D5 receptor have undetectable expression levels in 
the striatum (Hurley and Jenner, 2006). Canonically, dopamine binds D1 or D2, which activate 
Gs or Gi, which stimulate or inhibit adenylyl cyclase, respectively (Figure 1). D1 expressing 
MSNs preferentially localize to the caudate, where they innervate the substantia nigra pars 
reticulata (Bertran-Gonzalez et al., 2008). D2 MSNs preferentially localize in the putamen to 
innervate the globus pallidus (Bertran-Gonzalez et al., 2008).  
However, recent evidence has found populations of MSNs that co-express both D1 and 
D2 receptors. Reports on the prevalence of D1-D2 co-expressing MSNs has been widely 
variable. However, D1 and D2 co-expression is believed to be more prevalent during MSN 
development. When day 18–19 rat striatum was grown in monoculture for 14 – 21 days, 
“virtually all” of MSNs were found to co-express both D1 and D2 (Aperia et al., 2000). This is in 
contrast to the adult rat brain, where MSN co-expression was found to be as low as 1.9% in the 
dorsal striatum (Gagnon et al., 2017).    
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In MSNs co-expressing both D1 and D2, a novel signaling mechanism has been found to 
occur, as a result of the formation of the D1-D2 heteromer. This D1-D2 heteromer is coupled to 
Gq, which activates phospholipase C (PLC) to eventually generate an intracellular calcium signal 
as shown in Figure 2 (Lee et al., 2004; Hasbi, O'Dowd and George, 2011; Rico et al., 2016). This 
novel D1-D2 heteromer dependent mechanism has been linked to increased neuronal growth, 
synaptic plasticity, schizophrenia, and depression (Perreault et al., 2010; Hasbi, O'Dowd and 
George, 2011; Pei et al., 2010). For example, a post mortem study revealed that humans with 
major depressive disorder had a significantly higher proportion of D1-D2 heteromers than 
control subjects, and that disruption of the heteromer had an anti-depressant effect in rats (Pei et 
al., 2010). In terms of characterizing the D1-D2 heteromer itself, the D1-D2 heteromer was 
found to be already synthesized and preassembled in the Golgi apparatus, and is translocated to 
the plasma membrane as a heteromer (Rico et al., 2016). The D1-D2 heteromer is connected by 
the carboxy terminus of the D1 receptor and the third intracellular loop of the D2 receptor (Hasbi 
et al., 2014).  
Hasbi et al. used confocal fluorescence resonance energy transfer (FRET) to visualize the 
D1-D2 heteromer. Striatal neurons were exposed to two fluorophore labeled antibodies, one 
highly specific to the D1 receptor, the other specific to the D2 receptor. If the antibodies are in 
close proximity (average distance of 4 – 7 nm apart), a FRET signal will be generated due to 
energy transfer between fluorophores (Hasbi et al., 2009). Thus, MSNs with D1-D2 heteromers 
on their plasma membrane can be visualized as a FRET signal. In the adult rat brain, D1-D2 
heteromers were visualized in situ, but limited to neurons in the nucleus accumbens, which itself 
only had 25% of neurons co-expressing D1 and D2 (Hasbi et al., 2009). In contrast, earlier in 
development, Hasbi et al. found that 90% of postnatal rat striatal neurons co-express D1 and D2, 
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which were distributed through the whole striatum (2009). They also confirmed that the D1-D2 
heteromer used a Gq and PLC-dependent signal, resulting in intracellular calcium release (Figure 
2). Like Hasbi et al., our lab is looking to support the hypothesis that the D1-D2 heteromer, Gq 
and the PLC pathway is a key mechanism that has physiological relevance in regulating the 
growth and dendritic branching of MSNs.  
 
1.2 Goal 
The goal of the current study is to find the mechanism by which dopamine increases 
branching. We hypothesize that dopamine increases branching by activating a D1-D2 heteromer 
coupled to Gq to activate a PLC-dependent mechanism, as shown in Figure 2. To test this, we 
grew striatal cortical co-cultures from embryonic day 16 mice for 19 days in vitro (div), with 
chronic drug administration. Our treatments involved adding specific activators or inhibitors of 
upstream proteins in Figure 2 to the striatal-cortical co-culture. The degree of dendritic branching 
of the resulting MSNs was then quantified using Sholl. The results indicate that dopamine 
stimulates the D1-D2 heteromer coupled to Gq to activate a PLC-dependent mechanism to 
increase dendritic branching in developing MSNs.  
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2 Methods 
 
2.1 Animal Procedures 
Animal procedures were performed at the University of Minnesota in facilities accredited 
by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) 
and in accordance with protocols approved by the University of Minnesota IACUC, as well as 
the principles outlined in the National Institute of Health Guide for the Care and Use of 
Laboratory animals. 
 
2.2 Coverslip Preparation 
The coverslip preparation was done several weeks prior to the dissection. Circular 12 mm 
German glass coverslips (Bellco; 1943-10012) were acid washed in 1 M HCl solution overnight 
at 55 °C, washed three times for 30 minutes with milli-Q water and then sequentially rinsed in 
50%, 75%, and 95% solutions of ethanol, with 30 minute incubation periods at room temperature 
with each rinse. The coverslips were dried and maintained in an oven at 225°C.  
Coverslip coating was performed the day before the dissection. Coverslips were 
transferred to 35 mm petri dishes, with five coverslips per one 35 mm petri dish. The coverslips 
were coated in a mixture containing 100 µg/ml poly-D-lysine (PDL, Sigma; p7886) and 4µg/ml 
laminin (Invitrogen; 23017015). Poly D-lysine solution was made by dissolving 100 mg of PDL 
in 0.1 M borate, pH 8.5. PDL/borate was passed through a 0.2 µm filter to remove particulate 
matter, aliquoted, and stored at −80°C. Laminin was thawed on ice, aliquoted and stored at 
−80°C. Right before coverslip coating, PDL was thawed at 32°C and laminin was thawed slowly 
on ice. Each coverslip was coated with 50 µL of PDL/laminin. The petri dish was then sealed 
with parafilm and incubated overnight at room temperature. After incubation, cells were rinsed 
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three times with sterile water and 2 mL of neuronal plating media was added to each 35 mm petri 
dish. The dishes were stored in the cell culture incubator until the cortical and striatal cells were 
ready to be plated.  
 
2.3 The Dissection  
A schematic of the striatal cortical dissection and plating process is shown in Figure 3. A 
mouse pregnant with day 16 fetuses was sacrificed by cervical dislocation. Her abdomen was 
sprayed with 70% ethanol, and sterilized serrated forceps and scissors were used to cut open her 
abdomen. The horns of the uterus were removed and placed into a sterile petri dish. All 
subsequent steps were performed in the hood while looking through a dissecting microscope at 
the fetuses. The fetuses, about 1.2 to 1.5 cm long at this developmental stage, were removed 
from the uterus and decapitated with serrated forceps. The heads were placed in the 10 cm petri 
dish with ~15 mL calcium and magnesium free Hank's Balanced Salt Solution (CMF-HBSS) for 
rinsing. The heads were then transferred to one sterile paraffin dissecting dish with CMF-HBSS 
so the brain could be removed from the cranium. The brain isolation and all subsequent steps of 
plating the neurons are shown in Figure 3. The brain isolation was done using the forceps to stab 
through the eyes and peeling back the thin skin and skull layer with another pair of forceps, as 
shown in Step 1 of Figure 3. The brain was then transferred to the second paraffin dissecting 
dish. The diencephalon and brain stem were discarded, leaving the cerebral hemispheres (Step 
2). The cerebral hemispheres were isolated from all the mouse embryos at once. The meninges 
were removed from the cerebral hemispheres (Step 3). The angled forceps were used to scoop 
out the striatum from the medial side of the cerebral hemisphere (Step 4a). The striatum was 
placed in the 60 mm petri dish with 5 – 10 mL CMF-HBSS. The first third of the rostral end of 
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the cortex was cut out using the angled forceps (Step 4b). The cortex piece was placed in a 
separate 60 mm petri dish with 5 – 10 mL CMF-HBSS. Both tissues in their respective petri 
dishes were then chopped with a sterile razor blade. The chopped striatum was sucked up with a 
pipette and added to a 1.5 mL microcentrifuge tube labeled “S” (Step 6). The chopped cortex 
was added to a separate microcentrifuge tube labeled “C” (Step 6). To both tubes, 100 µL of 10 
X trypsin EDTA and 2 µL of benzonase was added (Step 7). The tube was gently inverted and 
incubated 30 min at 37°C, with gentle inversions every 5 to 10 minutes during incubation (Step 
8). The supernatant was removed from the settled tissue at the bottom of the microcentrifuge 
tube. Three 5 minute room temperature CMF-HBSS rinses were performed (Step 9). The tissue 
was then dissociated with a fire polished Pasteur pipette, with the tip size reduced to about half 
of normal (Step 10). The tissue was triturated with the Pasteur pipette approximately 10 times. 
The cell concentration of both striatum and cortex was counted using trypan blue and a 
hemocytometer (Step 11). The number of live and dead cells were recorded to assess cell 
viability, and these cells were plated as long as the viability was ≥	90%. That number of live 
cells was used to determine the volume of tissue solution to add to the petri dishes containing the 
acid washed coverslips and the neuronal plating media. For all low density cultures using 35 mm 
dishes, 150,000 cells per dish were plated in a 3:2 cortex to striatum ratio (Step 12).   
 
2.4 Cell Culture  
After adding cells from both striatum and cortex to the dishes, the dishes were gently 
rocked in a 2 dimensional plus configuration to spread the cells to all areas of the dish. The cells 
were incubated at 37°C for 2 – 4 hours to allow the cells to adhere. The neuronal plating media 
was removed and replaced with growth media (0.1X Neurobasal, 1X B27, 0.2 mM Glutamine) 
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that was conditioned 24 – 48 hours on confluent glia cultures. Glia cultures were prepared by 
growing cortical tissue from postnatal day 1 – 2 mice in glia plating media (Earle’s Modified 
Engle’s Medium, 10% fetal calf serum, 0.6% glucose, 0.2 mM glutamine, 1 mM sodium 
pyruvate, and 1x penicillin-streptomycin). Glia cultures are then grown to 90 – 100% 
confluency, which takes 2 – 3 weeks, at which time they can used for cell culture. (For more 
detail on how to make glia conditioned media, see Penrod et al., 2011, section 2.8.) At 4 div, glia 
conditioned media was removed and replaced with fresh, unconditioned growth media. On day 7 
and 14 div, half of the media was replaced with fresh, unconditioned growth media. Each of the 
three experiments in this study included a dopamine ((+)DA) treatment. For the (+)DA 
treatment, the cell culture was supplemented with 1 µM dopamine every 3 – 4 days, beginning at 
4 div. Like dopamine administration, the experimental treatment was added to the cultures 
beginning on 4 div and every 3 – 4 days thereafter.   
 
2.5 DNA Electroporation 
The mCherry tagged DREADD (Designer Receptor Exclusively Activated by Designer 
Drugs) plasmid encodes for a modified human acetylcholine receptor, only stimulated by the 
inert, designer drug Clozapine N-oxide (CNO).   
Nucleofection reagents A and B and 20 µg of the Gq DREADD plasmid were combined. 
Separately, the striatal neurons were dissociated in plating media immediately after the tissue 
was harvested. The cell number and viability with Trypan blue was used to determine the neuron 
concentration, and 106 cells were transferred to a microcentrifuge tube. Neurons were gently 
spun in the microfuge at 1000 g for 5 minutes. The supernatant was removed, and immediately 
the neurons were resuspended in Nucleofection reagent/plasmid mix. The nucleofection 
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reagent/plasmid/neuron solution was transferred to the nucleofection cuvette. The nucleofection 
cuvette was placed into the nucleofector and electroporated with the program 0-005 Neuron, 
Mouse Hippocampal. To the cuvette, 500 µL of warmed and pH equilibrated plating media was 
added. The electroporated neurons were removed from the cuvette and placed in warm plating 
media, yielding a final volume of 2 mL.  
 
2.6 Immunofluorescence 
Coverslips were fixed with 4% paraformaldehyde/PHEM (60 mM PIPES pH .0, 25 mM 
K-HEPES pH 7.0, 10 mM EGTA, 2 mM MgCl2)/0.12 M sucrose-buffered fixative at 37°C for 30 
minutes. The coverslips were then rinsed with 1 X PBS (phosphate buffered saline) and blocked 
with approximately 1 mL 3% RIA grade BSA (bovine serum albumin) in PBS and incubated 
overnight at 4°C. After incubation, BSA was removed and the neurons were permeabilized with 
1 mL of 0.2% Triton X-100 in PBS for 10 minutes at room temperature. The cells were rinsed 
with PBS. The cells were then blocked with 3% RIA grade BSA in 1 X PBS and incubated for 
30 minutes at room temperature. After incubation, coverslips, cell side up, were transferred to a 
staining box with a hydrophobic surface and overlaid with primary antibody in 1% RIA 
BSA/PBS.  The staining box was closed to reduce evaporation and the coverslips were incubated 
at 4°C overnight. All antibody mixtures contained polyclonal rabbit anti-Dopamine and cyclic 
AMP regulated phospho-protein of 32 kDa (DARPP-32; Cell signaling, cat. #2303, 1: 250), 
because MSNs highly express this protein. After incubation in the primary, the coverslips were 
rinsed in 1 X PBS for 5 min. The coverslips, cell side up, were then overlaid with secondary 
antibody, in a 1:100 dilution, in 1% BSA for 1 h. Secondary antibody was conjugated to either 
Alexa488 or Alexa594. Following secondary incubation, coverslips were rinsed in 1X PBS and 
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mounted on glass slides with 2.5% 1,4-Diazabicyclco-[2.2.2]Octane, 150 mM Tris pH 8.0, and 
80% glycerol mountant.  
 
2.7 Imaging 
MSN were identified by their high level of expressed DARPP-32 and imaged using a 
20X objective on a Zeiss Axiovert 200M microscope controlled by MicroManager Software. 
 
2.8 Quantification of Dendritic Branching 
Neurons were traced using the Simple Neurite Tracer software plugin for Fiji/ImageJ. A 
traced neuron in Simple Neurite Tracer included the number and length of primaries and 
dendritic branches. This data was used to generate Figure 4(b)-(e). A traced neuron could also be 
analyzed with Sholl analysis. Sholl analysis was used to quantify the level of dendritic 
arborization of each individual neuron. The Sholl analysis feature of Simple Neurite Tracer 
placed concentric rings radiating from the center of the neuron’s soma. Ring number was used as 
the x-axis value for the Sholl analysis figures (Figure 4a, 5, and 6), where ring 1 was the most 
proximal to the neuron’s soma, and ring 14 was the most distal from the neuron’s soma. Ring 1 
had a radius equal to 10.7 µm, and each subsequent ring had a ring radii equal to 10.7𝑛 µm, 
where 𝑛 is the ring number. Every time a dendrite crossed a ring loci, that counted as one 
crossing. The total number of crossings was the y-axis value. For example, the prototypical 
neuron in the dopamine treatment had a maximum number of dendritic branches (~13 crossings) 
at ring number 5 – 6 (Figure 4a).   
Replications from 2 – 3 independent cultures were pooled per experiment. Crossings 
were compared at each ring number and between experimental treatments using a two-way 
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ANOVA with Bonferonni’s post-test to determine significant differences where p ≤ 0.05 was 
significant. 
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3 Results 
The Lanier lab has found that dopamine increases dendritic branching in the developing 
MSN (Penrod et al. 2015). The goal of the current study is to find the mechanism by which 
dopamine accomplishes this. Three experiments were performed. In each experiment, we 
quantified dendritic branching by neurite tracing and Sholl analysis. All three experiments 
confirmed the previous finding that dopamine addition to the cultures resulted in increased 
dendritic branching from ~30 µm to ~90 µm from the soma.   
 
3.1 D1 and D2 Receptor Agonists Fail to Replicate Dopamine’s Branching Effects 
 The goal of the first experiment was to find the receptor(s) dopamine binds to increase 
branching. To do this, we selectively activated dopamine receptors by administering dopamine 
receptor agonists to the cultures at the same frequency dopamine was administered. We used 
three treatments: SKF81297, quinpirole, and SKF81297 & quinpirole. SKF81297 is a D1 
receptor agonist and would activate the Gs signaling cascade shown on the left in Figure 1, as in 
the D1 MSN. Quinpirole is a D2 receptor agonist, and would activate the Gi signaling cascade 
shown on the right in Figure 1, as in the D2 MSN. SKF81297 & quinpirole would activate D1 
receptors (Gs), D2 receptors (Gi), and the D1-D2 heteromer (Gq) (Lee et al., 2004).  
The three agonist treatments were administered to MSNs and their resulting degree of 
dendritic branching was quantified using Sholl (Figure 4a). This experiment was done under the 
assumption that each long-term treatment would result in long-term activation of its associated 
pathway(s). As expected, (+)DA caused significantly more dendritic branching at rings 4 – 9, 
compared to (–)DA (p ≤	0.05) (Figure 4a). Quinpirole had no effect on dendritic branching, with 
similar mean number of crossings as (–)DA at all ring loci (Figure 4a). SKF81297 and 
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SKF81297 & quinpirole appeared to cause an increase in proximal dendritic branching and a 
decrease in distal branching (p ≤ 0.05) (Figure 4a). Specifically, compared to (–)DA, SKF81297 
containing treatments had increased dendritic branching at ring 2 and ring 3, while dopamine 
does not increase branching until ring 4 (p ≤ 0.05) (Figure 4a). The SKF81297 & quinpirole 
treatment reached its maximum number of crossings at ring 4, being significantly more branched 
than (–)DA at this position (p ≤ 0.0001). Both SKF81297 containing treatments have fewer 
mean crossings than (–)DA by ring 8, and become significantly less branched at ring 10  (p ≤ 
0.05) (Figure 4a). These results indicate that none of the treatments replicated the effects of 
dopamine. 
The Sholl analysis provides information on the relative amount of branching between 
treatments, but cannot provide information on the number and length of primaries and dendrite 
branches. Analysis of the tracing data revealed that no treatment significantly changed the 
number of primaries (Figure 4b). Dopamine did increase the length of the primaries (p ≤	0.01) 
(Figure 4b). In contrast, SKF81297 reduced the length of the primary neurites in comparison to 
(–)DA (p ≤	0.05). Quinpirole and SKF81297 & quinpirole had no effect on the primary neurite 
length (Figure 4c). Dopamine addition caused an increase in the total number of dendritic 
branches off of primaries, including secondary, tertiary, and quaternary branches (p ≤ 0.01) 
(Figure 4d). SKF81297 & quinpirole also caused an increase in the total number of branches, 
though not to the same extent as dopamine (p ≤	0.05) (Figure 4d). Neither SKF81297 nor 
quinpirole alone had an impact on the number of branches (Figure 4d). When the length of all the 
dendritic branches was summed, it was found that dopamine addition increased the length of 
dendritic branches (p ≤	0.001) (Figure 4e). None of the agonist treatments had any effect on the 
total sum length of branches compared to treatment without dopamine ((–)DA) (Figure 4e).   
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3.2 Gq activation using a Chemogenetic Approach  
Analysis of the results in Figure 4 led us to hypothesize that dopamine acted through a 
different pathway from the canonical mechanism (Figure 1). The scientific literature suggests 
that dopamine can also act through the mechanism shown in Figure 2, in which activation of Gq 
is an essential upstream step. Although long-term SKF81297 and quinpirole treatment did not 
replicate dopamine, we believe this may be due to differences in receptor recycling induced by 
dopamine compared to SKF81297 & quinpirole (see discussion). Therefore, to directly 
determine if Gq activation was sufficient to replicate dopamine’s effects, Gq was activated by 
administering Clozapine N-oxide (CNO) to mCherry tagged, DREADDs expressing MSNs 
(Figure 5). Prior to coverslip plating, striatal tissue was electroporated with a plasmid that 
encodes a designer receptor (DREADDs) that couples to the endogenous Gq. Nanomolar 
concentrations of CNO selectively stimulate the receptor and by extension, Gq (Zhu and Roth, 
2014). It was found that 25 nM and 50 nM CNO were too highly concentrated to allow 
transfected MSNs to survive to day 19. Transfected MSNs were not growing because Gq was 
being overstimulated, resulting in toxic levels of intracellular calcium release (Figure 2). 
Fortunately, it was found that a 12.5 nM concentration of CNO was low enough to allow for 
normal MSN development. Thus, co-cultures electroporated with DREADDs were treated with 
long-term 12.5 nM CNO administration. If Gq is the only G protein activated in dopamine’s 
increased branching effect, there should be no significant differences in the Sholl between the 
dopamine treatment and Gq activation by the CNO treatment. It was found that the dopamine 
treatment had slightly more branched dendrites than the CNO treatment to transfected neurons, 
however, no significant differences between (+)DA and (+)CNO were found (except at ring 6)
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(Figure 5). As expected, dopamine addition caused increased branching from ring 2 – 11 (p ≤ 
0.05). Similarly, adding CNO to Gq coupled DREADDs neurons resulted in greater branching 
compared to (–)DA from ring 2 – 8 (p ≤ 0.05).  These data indicate that direct activation of the 
Gq pathway has an effect on MSN branching similar to that of dopamine.  
 
3.3 PLC antagonist U71322 Reduces Dopamine’s Branching Effect     
The goal in experiment 3 was to find if the activator enzyme phospholipase C (PLC) is 
required for dopamine to increase dendritic arborization, as in the novel mechanism (Figure 2). If 
PLC activation is necessary to increase branching, blocking PLC will significantly reduce 
dopamine’s branching effect. U73122 is a PLC antagonist with DMSO as the vehicle. MSNs not 
treated with U73122 were treated with DMSO to ensure the vehicle was in no way responsible 
for changing MSN dendritic branching. As expected, DMSO(+)DA had a significantly increased 
dendritic arbor from DMSO(–)DA (p ≤ 0.0001) from ring 3 – 7, and ring 8 (p ≤ 0.05) (Figure 
6).   
U73122 alone (U73122(–)DA) was administered to the cultures to see if blocking 
phospholipase C would decrease branching from basal DMSO(–)DA levels. Blocking PLC did 
not significantly alter branching from basal levels. This finding means that any differences in 
branching between DMSO(+)DA and U73122(+)DA is a result of a block in dopamine’s 
pathway to increase branching. It was indeed found that adding U73122 significantly decreased 
dopamine’s branching effect at rings 3 – 7 (p ≤ 0.05). This means that dopamine’s increase in 
branching is PLC-dependent.  
U73122(+)DA was also compared to U73122(–)DA, to see if dopamine could increase 
branching without PLC activation. If dopamine’s branching effect is PLC-dependent and 
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U73122 completely blocks PLC, we would expect that U73122(+)DA would not have any 
significant differences from U73122(–)DA. This is indeed supported by Figure 6 for most ring 
loci. The only locations where there is a significant difference between U73122(+)DA and 
U73122(–)DA is at intermittently spaced rings 3, 6, and 8 (p ≤ 0.05). This means that the 
increase in branching by adding dopamine (DMSO(+)DA vs. DMSO(–)DA) is significantly 
greater than the increase in branching by adding dopamine in the presence of a PLC inhibitor 
(U73122(+)DA vs. U73122(–)DA). These data show that dopamine increases dendritic 
branching by a PLC-dependent mechanism.  
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4 Discussion 
We have previously shown that dopamine increases dendritic branching in developing 
MSNs. Our current results demonstrate that dopamine does this by a Gq and PLC-dependent 
mechanism, consistent with the novel signaling pathway in which dopamine acts through a D1-
D2 heteromer (Figure 2).  
 
4.1 The Role of the D1-D2 Heteromer in Increasing Branching  
The accumulation of data from Figure 4(a)-(e) was used to deduce the morphology of a 
prototypical neuron from each treatment (Figure 7). The dopamine treatment results in increased 
primary length, and increased number and length of dendritic branches. The quinpirole has no 
effect, across any figure. In the Sholl, both SKF81297 and SKF81297 & quinpirole appear to 
increase proximal branching and decrease distal branching (Figure 4a). Figure 4(b)-(e) re-affirm 
that SKF81297 & quinpirole cause an increase in short, proximal branches and a decrease in 
distal branches. Figure 4b shows that SKF81297 has short primaries which explains why 
dendritic branching is low distally. It is clear that the dopamine receptor agonists failed to 
replicate dopamine’s branching effect (Figure 7).  
There are several possible reasons why dopamine receptor agonists fail to replicate 
dopamine, including: (1) SKF81297 and quinpirole fail to activate their respective receptor, (2) 
The long duration of agonist application could lead to unexpected effects on receptor function 
and (3) There are other dopamine signaling pathways besides Gs and Gi. 
SKF81297 was determined to have a high efficacy in activating adenylyl cyclase, in both 
in vitro and in vivo systems (Andersen and Jansen, 1990). It is well established that SKF81297 is 
a selective, full agonist of the D1 receptor (Andersen and Jansen, 1990). Quinpirole is a 
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selective, full agonist of the D2 receptor (Eilam and Szechtman, 1989). Further, both SKF81297 
and quinpirole altered MSN arborization, though not in the same way as dopamine, indicating 
that the agonists were active. Thus, it is very unlikely that SKF81297 and quinpirole failed to 
activate their respective dopamine receptors.  
A major difference between our study and previous studies that used SKF81297 and 
quinpirole to mimic the effects of dopamine is the duration of agonist exposure. In our lab, the 
co-culture was exposed to their respective treatment for 15 days. In contrast, previous studies 
measured intracellular changes from treatment addition on the order of seconds, minutes, or at a 
maximum of three hours after administration (Tang and Bezprozvanny, 2004; Bartlett et al., 
2005). Lee et al. found that in MSNs co-expressing both D1 and D2 receptors, adding both 
SKF81297 & quinpirole for 20 minutes induced a PLC-dependent calcium signal similar to that 
induced by dopamine (2004). In an apparent contrast, our lab found that SKF81297 & quinpirole 
did not mimic the effect of dopamine on branching (Figure 4a). Comparison of the data from So 
et al. and Bartlett et al. help resolve this discrepancy (2005).    
 So et al. used human embryonic kidney cell line (HEK293) to study the internalization of 
dopamine receptors in cells co-expressing both D1 and D2 receptors (2005). Prolonged 
stimulation of either D1 or D2 receptor triggers invagination around the dopamine-receptor 
complex, which will pinch off from the plasma membrane to form an intracellular vesicle (i.e. 
endocytosis). After a 30 minute treatment with dopamine, or SKF81297, or quinpirole, both D1 
and D2 receptors were internalized together as the D1-D2 heteromer (So et al., 2005). This 
means that activating one receptor can cause the D1-D2 heteromer to endocytose as one.  
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Bartlett et al. also used HEK293 cells, but these cells only expressed one dopamine 
receptor monomer, D1 or D2. After a 60 minute dopamine treatment, both the D1 and D2 
receptor monomers were internalized (Bartlett et al., 2005). As an intracellular vesicle, however, 
the D1 and D2 receptors have different fates (Bartlett et al., 2005). The D1 receptor is quickly 
recycled back to the surface of the plasma membrane. Meanwhile, the D2 receptor is degraded as 
a result of interacting with a GPCR associated signaling protein (GASP) (Bartlett et al., 2005). 
Thus, new D2 receptors have to be synthesized and translocated to the plasma membrane before 
D2 receptor signaling can occur again. The net result is downregulation of D2 receptor signaling. 
 Taking these separate studies into context, our dopamine receptor Sholl results (Figure 
4a) can be explained as follows. When the neurons are treated with SKF81297, the D1 receptor 
endocytoses and is quickly recycled to the surface repeatedly over time, causing a prolonged Gs 
and adenylyl cyclase dependent signal (Bartlett et al., 2005). When the cultures are treated with 
quinpirole, quinpirole bound to the D2 receptor endocytoses and GASP mediated degradation of 
the D2 receptor takes place (Bartlett et al., 2005). Over 15 days, the D2 receptor is rarely 
activated because D2 receptors must be continuously synthesized. This explains why no 
significant differences between quinpirole and (–)DA were found (Figure 7). For the SKF81297 
& quinpirole treatment, both agonists bind the D1-D2 heteromer and endocytosis of the 
heteromer takes place (So et al., 2005). We hypothesize that quinpirole bound to the D1-D2 
heteromer still allows for GASP to degrade the D2 receptor. Thus, only the D1 receptor is 
immediately recycled and returned to the surface of the plasma membrane, which will result in 
prolonged activation of Gs and adenylyl cyclase, same as SKF81297 only. This would explain 
the high degree of similarity in the Sholl for SKF81297 and SKF81297 & quinpirole. The ring 4 
locus in SKF81297 & quinpirole that has a comparatively greater mean number of crossings than 
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SKF81297 can be ignored. Since it’s only one ring locus, we will view that maximum value as a 
product of chance. 
To explain why long-term treatment with dopamine has a different effect than long-term 
applications of SKF81297 and quinpirole, we hypothesize that these treatments trigger different 
recycling/degradation pathways. We propose that dopamine binds a D1-D2 heteromer. 
Prolonged dopamine in the environment will cause the D1-D2 heterodimer to endocytose. Upon 
endocytosis, we could hypothesize that GASP cannot interact with the dopamine-D1-D2 
heteromer complex. In this view, dopamine, unlike SKF81297 or quinpirole, causes the D1-D2 
heteromer to change conformation in a way that prevents GASP interaction. Thus, D2 is not 
degraded, and the heteromer returns to the surface, allowing continuous Gq signaling to occur, 
resulting in the significant morphological changes we see by dopamine addition (Lee et al., 
2004).   
Future experiments will focus on testing the hypothesis that dopamine protects the D1-D2 
heterodimer from degradation, thus allowing long-term Gq signaling that leads to enhanced 
branching. To determine whether increased branching requires activation of the D1-D2 
heteromer, a peptide that disrupts the heteromer (Hasbi et al., 2014), could be added with 
dopamine. If the heterodimer is essential, then this treatment should block the ability of 
dopamine to induce branching. A complementary test would be to add SKF83959, which has 
found to be a specific D1-D2 heteromer agonist and should thus mimic the effects of dopamine 
on branching. 
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4.2 The Role of Gq in Increasing Branching 
Our DREADDs experiment supports the conclusion that direct activation of Gq can 
increase dendrite branching (Figure 5). Adding CNO was found to mimic dopamine in neurons 
transfected with DREADDs (Figure 5). However, Gomez et al. found that in vivo, 10 µM CNO 
can be converted to clozapine, which inhibits many receptors, including D1 and D2 (2017). 
Despite this, we do not believe significant amounts of CNO are being metabolized to clozapine 
in our cultures because (1) The increase in dendritic branching by CNO is not consistent with 
dopamine receptor inhibition and (2) The concentration of CNO our lab used was approximately 
1000 fold less than Gomez et al.  
However, to ensure that CNO being converted to clozapine is not the cause of increased 
dendritic branching, our DREADDs experiment will be repeated with the following controls: 
untransfected MSNs with and without CNO, and transfected with and without CNO. 
Untransfected MSNs without CNO is just the (–)DA treatment, and untransfected with CNO 
should look identical to (–)DA, because in the absence of the designer receptor, 12.5 nM CNO 
should not alter MSN growth.  
To confirm the role of Gq in increasing branching, future experiments will administer 
both dopamine and a specific Gq inhibitor (YM 254890) to the co-culture (Takasaki et al., 2004). 
There will be four treatments, as the PLC inhibitor experiment, to establish that a certain 
concentration of Gq inhibitor alone does not affect basal dendritic branching levels.  
 
4.3 PLC Inhibition Attenuates Dopamine’s Increased Branching Effects 
Inhibiting PLC in the presence of dopamine significantly reduced dopamine’s ability to 
increase branching (Figure 6). This is the strongest evidence we have to support the hypothesis 
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that dopamine increases dendritic branching by a Gq and PLC-dependent mechanism. This 
hypothesis is supported by the finding that the PLC inhibitor alone had no impact on basal levels 
of dendritic growth. It was a pleasant surprise that chronically inhibiting PLC had no effect on 
dendritic branching or cell viability. Tang and Bezprozvanny added 10 µM PLC inhibitor 
U73122 for 10 minutes to demonstrate that calcium signaling is PLC-dependent (2004). We 
decided that a 100 fold reduction in that concentration may suffice to continuously inhibit PLC, 
yet still maintain cell viability long-term. It was found that 100 nM U73122 was an appropriate 
concentration to both effectively attenuate dopamine’s effects, and not decrease branching when 
administered alone. 
 
4.4 Conclusion 
 The goal of the current study was to find what mechanism dopamine activates to 
ultimately increase dendritic branching in striatal neurons. Understanding the mechanisms 
involved in neuronal growth can bring insight to the origins of neurodevelopmental disease, as 
well as disorders involving aberrant dopamine signaling, such as schizophrenia and depression.  
In summary, we provide support for the theory that dopamine increases branching by 
binding a D1-D2 heteromer coupled to Gq, which activates a PLC-dependent mechanism. The 
role of the D1-D2 heteromer in this mechanism needs further support, so co-cultures will be 
treated with SKF83959, a specific D1-D2 heteromer agonist (Rashid et al., 2006). In addition, 
more evidence is needed support the hypothesis that Gq activation is required to increase 
dendritic branching. The possibility of CNO being converted to clozapine in our cultures must be 
eliminated, by employing additional controls as described. Our lab found that PLC inhibition 
strongly attenuated dopamine’s effects on increasing dendritic branching. In conclusion, our 
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study supports the hypothesis that dopamine increases dendritic branching in the developing 
Medium Spiny Neuron by binding a D1-D2 heteromer coupled to Gq to activate a PLC-
dependent mechanism.  
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Figures 
 
Figure 1. The Canonical Mechanism that follows Dopamine Receptor Monomer Activation. 
In this schematic, dopamine (DA) binds receptor on a MSN expressing only the D1 receptor (D1 
MSN, left) or a MSN only expressing the D2 receptor (D2 MSN, right). Additionally, an agonist 
such as SKF81297 can bind and activate the D1 receptor (left) and quinpirole can bind and 
activate the D2 receptor (right). When the D1 receptor coupled to the stimulatory G protein Gs is 
activated, adenylyl cyclase (AC) becomes active, and catalyzes the conversion of adenosine 
triphosphate (ATP) to cyclic adenosine monophosphate (AMP), which frees protein kinase A 
(PKA) to phosphorylate proteins and/or to enter the nucleus to alter transcription. In contrast, 
when the D2 receptor coupled to Gi is activated, adenylyl cyclase is inhibited, and cytosolic ATP 
can build up. Note: D1 and D2 MSNs do not differ in cell size—the D1 MSN appears larger in 
the schematic in order to include all of the downstream effects of cyclic AMP.   
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Figure 2: The Novel Mechanism that follows D1-D2 Heteromer Activation. This schematic 
shows the proposed mechanism by which dopamine increases dendritic branching. Dopamine 
(DA) binds the D1-D2 heteromer to activate Gq, which activates phospholipase C (PLC). PLC 
cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) to yield the products inositol 1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG). IP3 causes calcium (Ca2+) channels on the 
endoplasmic reticulum (ER) to open, resulting in intracellular calcium release. Calcium ions can 
activate protein kinase C (PKC) to phosphorylate proteins (green oval).  
 40 
 
Figure 3: Schematic of the cortical striatal dissection. For additional clarification, see 
Methods Section 2.3: The Dissection. Note: Images are not to scale.  
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Figure 4. Dopamine receptor activation and its effect on MSN dendritic arborization. (a) 
Sholl analysis of MSNs treated with DA receptor agonists. One treatment was 10 µM SKF81297, 
a full D1 receptor agonist (green). The next treatment was 10 µM quinpirole, a D2 receptor 
agonist (blue). The last treatment was 10 µM of each SKF81297 and quinpirole (purple). The 
significant differences of each treatment were compared to (–)DA (dotted black), using a two 
way ANOVA, where the absence of stars means the comparison was not significantly different. 
For (b) through (e), (+)DA (solid black) and all treatments were compared to (–)DA, using a one 
way ANOVA. “ns” means no significant difference was found between the particular treatment 
and (–)DA. For (a) through (e), all statistical differences were annotated with stars where *p ≤ 
0.05,  **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. Data displayed as Mean ± SEM. N = 78 – 178 
neurons for each treatment from two replicates.      
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Figure 5. Gq activation and its effect on MSN dendritic arborization. Sholl analysis of MSNs 
treated with 12.5 nM Clozapine N-oxide (+)CNO. Prior to coverslip plating, the striatal tissue in 
the (+)CNO treatment was electroporated with the mCherry tagged Gq coupled DREADDs 
(Designer Receptor Exclusively Activated by Designer Drugs) plasmid. CNO was the designer 
drug to activate the Designer Receptor coupled to Gq. Only MSNs expressing DREADDs were 
traced and analyzed with Sholl to generate the data to support (+)CNO. Significant difference 
pairings are indicated above the x axis. Three relationships were compared for significance: (–
)DA vs (+)DA (black), (–)DA vs (+)CNO (purple) and (+)DA vs (+)CNO (red) *p ≤	0.05, **p ≤	0.01, ***p ≤	0.001, ****p ≤	0.0001, using a two way ANOVA. Data displayed as Mean ± 
SEM. N = 113 – 123 neurons for each treatment from three replicates.  
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Figure 6. Phospholipase C antagonist U73122 and its effect on MSN dendritic arborization 
in the presence of dopamine. Sholl analysis of MSNs treated with 100 nM U73122 and (+)DA. 
Three different statistical analyses where compared, one between DMSO(+)DA and DMSO(–
)DA (black), one between U73122(+)DA and U73122(–)DA (blue), and the last one between 
DMSO(+)DA and U73122(+)DA (red). U73122 is a PLC antagonist in the vehicle DMSO, so 
equal volume DMSO was added to (–)DA and (+)DA as a control. The three statistical 
comparisons used a two way ANOVA where *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 
0.0001. Data displayed as Mean ± SEM. N = 79 – 99 neurons for each treatment.  
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Figure 7. The prototypical neuron in each treatment from the DA receptor agonist 
experiment. This figure was created as an accumulation of all the data from Figure 4(a) – (e). 
There were no significant differences between the (–)DA MSN and the quinpirole MSN. (+)DA 
increased the length of the primaries and increased the number and length of branches (p ≤ 
0.05). SKF81297 decreased primary length (p ≤ 0.05). SKF81297 & quinpirole increased the 
number of proximal branches. Note: Primary neurites are the lines extending directly from the 
soma. Secondaries are branches off the primaries. No tertiary or quaternary neurons are shown. 
These images are not to scale and the differences between treatments may be exaggerated for 
simplification purposes.    
 
 
